StopDown
Funding · 18 May 2026Cellogen TherapeuticsRs 20 croreDevelops cell and gene therapies for cancer

Cellogen raises Rs 20 crore from Kotak Alts

By · Editor ·

SeedFounded 2021
  • Cellogen develops CAR-T cell therapies for cancers using AI-driven platforms
  • The company raised Rs 20 crore led by Kotak Alternate Asset Managers
  • It targets lower treatment costs compared to global standards of $500,000

What happened

  • Cellogen Therapeutics has raised Rs 20 crore in funding from investors.
  • Kotak Alternate Asset Managers led the investment round via its fund.
  • The company plans to use funds for clinical programs and manufacturing expansion.
  • Cellogen is preparing for Phase I human clinical trials with CMC Vellore.
  • The startup aims to advance its gene therapy pipeline significantly this year.
  • Cellogen holds a patent for its proprietary CAR-T platform technology.
  • The firm operates a GMP-compliant facility in Noida for manufacturing.
  • Investors include existing backer Natco Pharma which holds a small stake.

Why it matters

  • Cellogen targets a price point of $60,000 to $70,000 per treatment.
  • This cost is significantly lower than global CAR-T therapies costing up to $700,000.
  • The Indian biotech sector supports over 11,000 startups currently.
  • Government schemes like Biopharma SHAKTI aid domestic biotech development efforts.

The business

  • Cellogen develops cell and gene therapies for treating various cancers.
  • It uses Chimeric Antigen Receptor T-cell (CAR-T) technology for treatments.
  • The core platform focuses on bispecific dual-antigen CAR-T therapy designs.
  • These therapies target two cancer markers to reduce patient relapse risks.
  • Early-stage programs address beta thalassemia and sickle cell disease conditions.
  • The company utilizes AI-driven platforms for designing new therapeutic agents.
  • A GMP-compliant facility in Noida handles in-house vector manufacturing.
  • Cellogen received a patent for its CAR-T platform technology recently.

The founders

Dr. Gaurav Kharya

Co-Founder
  • Co-founded Cellogen Therapeutics in 2021.
  • Leads the scientific direction of the company's research initiatives.

Dr. Tanveer Ahmad

Co-Founder
  • Co-founded Cellogen Therapeutics in 2021.
  • Works alongside Dr. Kharya on developing novel therapeutic solutions.

Who put in money

  • Kotak Alternate Asset Managers lead — Invests via Kotak Life Sciences Fund I.
  • Natco Pharma existing — Acquired a 5.38% stake for slightly over Rs 15 crore previously.

In numbers

Rs 20 croreFunding Amount · 2026
$60,000-$70,000Treatment Price Target
$500,000-$700,000Global CAR-T Cost
>11,000Indian Biotech Startups

What happens next

  • Cellogen will advance CAR-T clinical programs immediately after funding.
  • The company plans to expand its gene therapy pipeline offerings.
  • Regulatory approval is sought for Phase I trials with CMC Vellore.
  • Manufacturing and regulatory capabilities will be strengthened using new capital.

Earlier rounds

  • Prior to 2026 · Previous Stake Sale · Slightly over Rs 15 crore · led by Natco Pharma

Up against

ImmunoACT

Words to know

CAR-T
Chimeric Antigen Receptor T-cell therapy uses modified immune cells to fight cancer.
GMP
Good Manufacturing Practice ensures products are consistently produced to quality standards.
Lentiviral Vector
A virus-based tool used to deliver genetic material into cells for therapy.
Bispecific
Therapies designed to bind to two different antigens simultaneously for better targeting.

The numbers around it

Healthcare & Life Sciences in May 2026: 7 rounds with a disclosed amount, $11.9 million in all; the biggest was Gabit (₹36.2 Cr ($3.7 Mn)). Every sector this year →

Other articles talking about it

Read it as a card in the app

Terms in this story

  • Lead investor: A lead investor is the investor that sets the price and main terms of a funding round, does the deepest checks on the company and usually puts in the largest cheque. When a headline says a round was led by a fund, that fund was the first to commit and shaped the deal that others joined.

All startup news on 18 May 2026 →

Is this Cellogen Therapeutics? Get your “Featured on StopDown” badge →